Internal Medicine, Clinical Cardiatric Electrophysiology · Modesto, CA
NPI
1427025766
Since 2006
Specialty
Internal Medicine, Clinical Cardiatric Electrophysiology
Code 207RC0001X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1409 E Briggsmore Ave
Modesto, CA, 95355
Phone (209) 524-1211
Groups this clinician bills Medicare through
Medicare paid, 2024
$568K
8,338 services
Medicare patients, 2024
2,172
Average age 75
Drug cost, 2024
$1.1M
6,766 prescriptions
Company payments, 2025
$3,407
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Raman Moradkhan was code 99214 (office e&m - established), 1,104 times for 669 patients. In total Raman Moradkhan billed 8,338 services in 89 codes, and Medicare paid $568K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-06-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,104 | 669 | $93.36 | $103K |
| 93298 External Electrocardiographic Monitoring | Office | 875 | 129 | $75.87 | $66K |
| J2785 Injection, regadenoson, 0.1 mg | Office | 684 | 171 | $5.41 | $3,698 |
| 93010 Electrocardiogram | Facility | 649 | 516 | $6.19 | $4,020 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 642 | 533 | $13.04 | $8,374 |
| 93000 Electrocardiogram | Office | 541 | 509 | $10.94 | $5,920 |
| A9502 Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 385 | 192 | $75.91 | $29K |
| 93306 Echocardiography (TTE/TEE) | Office | 364 | 344 | $152.40 | $55K |
| 93296 External Electrocardiographic Monitoring | Office | 270 | 93 | $15.83 | $4,273 |
| 93306 Echocardiography (TTE/TEE) | Facility | 256 | 250 | $52.38 | $13K |
| 93294 External Electrocardiographic Monitoring | Office | 243 | 82 | $19.76 | $4,802 |
| 78452 Myocardial Perfusion Scan | Office | 193 | 193 | $365.17 | $70K |
| 99204 Office E&M - New | Office | 187 | 187 | $124.48 | $23K |
| 93015 Electrocardiogram | Office | 186 | 185 | $51.12 | $9,509 |
| 99215 Office E&M - Established | Office | 143 | 114 | $135.66 | $19K |
By year: 2022 $544K for 7,799 services; 2023 $519K for 7,349 services; 2024 $568K for 8,338 services.
Medicare prescription drug claims, 2024
In 2024, the drug Raman Moradkhan prescribed most often to Medicare patients was Metoprolol Succinate, with 858 prescriptions and refills. In total Raman Moradkhan wrote 6,766 Medicare prescriptions that cost $1.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Metoprolol Succinate Generic | 858 | 2,192 | 251 | $12K |
| Flecainide Acetate Generic | 660 | 1,702 | 191 | $32K |
| Amiodarone Hcl Generic | 589 | 1,406 | 189 | $11K |
| Eliquis Apixaban | 441 | 816 | 125 | $474K |
| Furosemide Generic | 364 | 806 | 111 | $2,208 |
| Metoprolol Tartrate Generic | 355 | 946 | 123 | $2,184 |
| Carvedilol Generic | 274 | 694 | 81 | $2,120 |
| Lisinopril Generic | 241 | 627 | 79 | $2,035 |
| Nifedipine Er Nifedipine | 228 | 524 | 70 | $4,809 |
| Atorvastatin Calcium Generic | 185 | 488 | 58 | $1,833 |
| Losartan Potassium Generic | 184 | 506 | 55 | $1,398 |
| Xarelto Rivaroxaban | 156 | 256 | 35 | $142K |
| Amlodipine Besylate Generic | 141 | 340 | 36 | $1,036 |
| Entresto Sacubitril/Valsartan | 132 | 207 | 26 | $138K |
| Valsartan Generic | 126 | 255 | 31 | $3,551 |
Brand drugs: 1,060 claims; generic drugs: 5,706 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Raman Moradkhan $3,407 ($3,407 in general payments such as food, travel and fees) from 4 companies. The largest payer was Abbott Laboratories with $3,180.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.